TAK-683 TFA, a potent full KISS1 receptor (KISS1R) agonist with a half-maximal inhibitory concentration (IC50) of 170 pM, exhibits enhanced metabolic stability. As a nonapeptide metastin analog, it demonstrates agonistic activities towards KISS1R, with effective concentration (EC50) values of 0.96 nM for humans and 1.6 nM for rats. In vivo, TAK-683 TFA reduces gonadotropin-releasing hormone (GnRH) levels in the hypothalamus and decreases plasma follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels. Given these effects, TAK-683 TFA holds promise for research into hormone-dependent prostate cancer.

TAK-683 is an effective full KISS1 receptor agonist (IC50=170 pM). TAK-683 is a nonapeptide metastin analog, shows agonistic activities to KISS1R (EC50: 0.96 nM and 1.6 nM for human and rat, respectively).

TAK-683 TFA is a potent full agonist of the KISS1 receptor (KISS1R; IC50: 170 pM) with improved metabolic stability. It shows agonistic activities to KISS1R (EC50s: 0.96 nM and 1.6 nM for human and rat).

TAK-683 acetate is a nonapeptide metastin analog and a potent full agonist of the KISS1 receptor (KISS1R), exhibiting IC 50 =170 pM and enhanced metabolic stability. This compound shows agonistic activities towards KISS1R, with EC 50 values of 0.96 nM and 1.6 nM for human and rat KISS1R, respectively. TAK-683 acetate effectively depletes GnRH in the hypothalamus and reduces plasma levels of FSH, LH, and testosterone in vivo, showcasing its potential for hormone-dependent prostate cancer research.